Table 2.
Drugs targeting different targets.
| ADC | mAb | Payload | Linker | DAR | Approved | Company | Year |
|---|---|---|---|---|---|---|---|
| Trastuzumab Emtansine (T-DM1) |
Trastuzumab | DM1 | Non-cleavable SMCC linker |
3.5 | HER-2 | Genentech | 2013 |
| Trastuzumab Deruxtecan (DS-8201a) |
Trastuzumab | Dxd | Cleavable GGFG linker |
7-8 | HER-2 | Daiichi Sankyo |
2021 |
| Disitamab Vedotin (RC48) |
Aidixi | MMAE | Cleavable vc-PABC linker |
4 | HER-2 | RemeGen | 2021 |
| Trastuzumab Duocarmazine (SYD985) |
Trastuzumab | Seco-DUBA | Cleavable vc linker |
2.7 | HER-2 | Byondis | 2017 |
| ARX-788 | Anti-HER2 mAb (ARX269) |
MMAF | Non-cleavable linker conjugated to pAcF |
1.9 | HER-2 | Ambrx | 2021 |
| A166 | Anti-HER2 mAb | Duostatin-5 | Cleavable vc linker |
N/A | HER-2 | Klus | 2021 |
| MRG002 | Anti-HER2 mAb | MMAE | Cleavable vc linker |
3.8 | HER-2 | Miracogen | 2020 |
| ALT-P7 | Trastuzumab biobetter (HM2) | MMAE | Cleavable cysteine-containing peptide linker |
2 | HER-2 | Alteogen | 2020 |
| GQ1001 | Trastuzumab | DM1 | N/A | N/A | HER-2 | GeneQuantum | 2022 |
| SBT6050 | Anti-HER2 mAb | Toll-like receptor 8 agonist |
N/A | N/A | HER-2 | Silverback | 2020 |
| PF-06804103 | Trastuzumab-derived Ab | Aur-0101 | Valine-citrulline linker | 4 | HER-2 | Pfizer | 2020 |
| Gemtuzumab Ozogamicin (MYLOTARG) |
Gemtuzumab | Ozogamicin/Calicheamicin | Acid cleavable linker |
2-3 | CD33 | Pfizer | 2017 |
| Brentuximab Vedotin (ADCETRIS) |
Brentuximab | MMAE | Enzyme Cleavable linker |
4 | D30 | Seagen | 2011 |
| Inotuzumab Ozogamicin (BESPONSA) |
Inotuzumab | Ozogamicin/ Calicheam-icin |
Acid cleavable linker |
6 | CD22 | Pfizer | 2017 |
| Polatuzumab Vedotin (POLIVY) |
Polatuzumab | MMAE | Enzyme Cleavable linker |
3.5 | CD79 b | Roche | 2019 |
| Enfortumab Vedotin (ADCEV) |
Enfortumab | MMAE | Cleavable linker | 3.8 | Nectin4 | Seattle Genetics | 2019 |
| ABT-414 | Anti-EGFR mAb | MMAF | Non-cleavable mc linker |
4 | EGFR | AbbVie | 2020 |
| MRG003 | Anti-EGFR mAb | MMAE | Non-cleavable mc linker |
N/A | EGFR | Miracogen | 2020 |
| M1231 | Anti-EGFR mAb | Hemiasterlin | N/A | N/A | EGFR | Sutro EMD Serono |
2021 |
| Sacituzumab Govitecan (TRODELVY) |
Sacituzumab | Govitecan | Cleavable linker | 7.6 | Trop2 | Immunomedics | 2020 |
| Sacituzumab Govitecan (IMMU-132) |
Sacituzumab | IMMU-132 | N/A | N/A | Trop 2 | Immunomedics | 2022 |
| SKB246 | Pembrolizumab | MMAE | Cleavable linker | 7.4 | Trop 2 | Kelun-Biotech | 2022 |
| DS-1062 | Datopotamab | DX-8951f | Acid cleavable linker |
4 | Trop 2 | Daiichi Sankyo |
2020 |
| SYSA1801 | Anti- Claudin 18.2 mAb | MMAE | Cleavable linker | 2 | Claudin 18.2 | CSPC | 2021 |
| CMG901 | Anti- Claudin 18.2 mAb | MMAE | Cleavable linker | 7.4 | Claudin 18.2 | Keymed | 2020 |
| RC118 | Anti- Claudin 18.2 mAb | MMAE | Cleavable linker | N/A | Claudin 18.2 | Remegen Co.,Ltd | 2021 |
| SKB315 | Anti- Claudin 18.2 mAb | MMAE | Cleavable linker | N/A | Claudin 18.2 | Kelun-Biotech | 2021 |